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Glial cells perform critical functions that alter the metabolism and activity of neurons, and there is increasing 
interest in their role in appetite and energy balance. Leptin, a key regulator of appetite and metabolism, has 
previously been reported to influence glial structural proteins and morphology. Here, we demonstrate that 
metabolic status and leptin also modify astrocyte-specific glutamate and glucose transporters, indicating that 
metabolic signals influence synaptic efficacy and glucose uptake and, ultimately, neuronal function. We found 
that basal and glucose-stimulated electrical activity of hypothalamic proopiomelanocortin (POMC) neurons 
in mice were altered in the offspring of mothers fed a high-fat diet. In adulthood, increased body weight 
and fasting also altered the expression of glucose and glutamate transporters. These results demonstrate that 
whole-organism metabolism alters hypothalamic glial cell activity and suggest that these cells play an impor-
tant role in the pathology of obesity.
Introduction
The pathophysiological function of glial cells has become a pri-
mary focus in the investigation of numerous diseases. Astrocytes 
appeared evolutionarily subsequent to neurons, augmenting in 
abundance and complexity in parallel with increasingly complex 
brain functions (1–3), which supports the concept that they play a 
more sophisticated role than previously considered. Indeed, these 
glial cells are fundamental for normal brain development and 
function, as they modulate neuronal proliferation, survival and 
metabolism, synaptogenesis, and synaptic transmission and main-
tain local extracellular homeostasis, with new and more complex 
functions continuing to be described (2, 3).
Astrocytes were reported to participate in diverse neuroendo-
crine processes over 2 decades ago (4, 5), although their impor-
tance in the control of appetite and energy balance has only 
recently come to the forefront (6–11). Astrocytes and tanycytes, 
the specialized glial cells lining the third ventricle, transport nutri-
ents into and within the brain, express receptors for numerous 
neuropeptides, neurotransmitters, and growth factors, produce 
neuroactive substances, and express key enzymes necessary for 
sensing and processing nutritional signals (2, 6, 12–15), situating 
them as prime targets for metabolic signals and control. Indeed, 
the diet-induced increase in leptin receptor (LepR) levels in hypo-
thalamic astrocytes is proposed to participate in obesity onset and 
perpetuation (7, 8, 16). Leptin also affects astrocyte morphology 
and synaptic protein levels in the hypothalamus and can rapidly 
induce synaptic changes in metabolically important neurons (9, 
17, 18). As astrocytes participate in the hormone-induced synaptic 
rearrangement involved in diverse neuroendocrine functions (4, 5), 
they may also control leptin-induced synaptic remodeling (17, 18).
Acute activation of glial cells can have beneficial effects on 
neurons, including reduction of oxidative stress (19). However, 
their long-term activation can have detrimental results, such as 
the release of inflammatory factors (20). Fatty acids have recently 
been shown to directly activate inflammatory signaling in astro-
cytes (21), suggesting that in addition to hormones, prolonged 
exposure to increased levels of specific metabolites could induce 
hypothalamic inflammation. However, little is known regarding 
the involvement of astrocytes in physiological metabolic control.
Communication between astrocytes and neurons is required for 
glucose to be used centrally as a fuel source, with astrocytes being 
primarily responsible for the captation of this substrate (22–24) 
through glucose transporter 1 (GLUT-1), which is highly expressed 
in the endfeet that envelop capillaries (25, 26). Not only is it an 
energy source, but central glucose levels also modulate systemic 
metabolism through a mechanism involving GLUT-2, expressed 
in hypothalamic astrocytes, ependymal-glial cells, tanycytes, and 
glucose-sensitive neurons (27–30). Expression of this transporter 
in astrocytes is fundamental for central glucose sensing and regu-
lation of food intake (30–33). In contrast, GLUT-3 is expressed 
primarily in neurons throughout the brain (34–36).
Glucose uptake is tightly coupled to neuronal activity, not only 
to meet neuronal energy requirements, but also to fuel the uptake 
and metabolism of neurotransmitters by astrocytes (22–24). Glu-
tamate, for example, is removed from the synaptic cleft by these 
glial cells, where it is metabolized to glutamine via glutamine 
synthetase (GS). This glutamine is then distributed to neurons to 
produce glutamate or, in the presence of glutamic acid decarboxyl-
ase (GAD), GABA (37, 38). This process not only directly regulates 
Conflict of interest: The authors have declared that no conflict of interest exists.
Citation for this article: J Clin Invest. 2012;122(11):3900–3913. doi:10.1172/JCI64102.
research article
 The Journal of Clinical Investigation   http://www.jci.org   Volume 122   Number 11   November 2012 3901
excitatory synaptic transmission and decreases synaptic spillover, 
but also prevents glutamate excitotoxicity (39–41). The glutamate 
transporter GLT-1 is expressed almost exclusively in astrocytes 
(42), while glial high-affinity glutamate transporter (GLAST) is 
found in astrocytes and other glial cells (43, 44). Hence, changes in 
the number or functioning of hypothalamic astrocytes could sub-
stantially modify synaptic transmission and efficiency, and thus 
neuroendocrine responses.
The maternal and early neonatal nutritional environments affect 
metabolic functions in the mature offspring, which can be at least 
partially attributed to modifications in the development of hypo-
thalamic circuits that control metabolism (9, 45–48) Changes in 
circulating leptin levels are proposed as one factor inducing these 
long-term changes, as this hormone affects neuronal development 
(49–51). However, although glial development is also leptin sensi-
tive, little is known regarding the outcome of early nutritional or 
hormonal changes on this cell type.
As glia perform a plethora of functions and hypothalamic astro-
cytes are clearly affected in obese and overweight animals (7–9, 11, 
16, 18), understanding their role in metabolic control is highly 
warranted. Here, we demonstrate that early nutritional changes 
can affect astrocyte number and morphology as well as physiologi-
cal functions, such as glucose sensing that involves glia. Moreover, 
we found glucose and glutamate transporters to be affected by 
metabolic status, with leptin directly modulating transport of 
these factors in hypothalamic astrocytes, indicating that these cells 
are indeed fundamental players in controlling energy homeostasis.
Results
Weight change, metabolic hormone levels, and hypothalamic 
neuropeptides in response to neonatal overnutrition. As 
previously reported (18, 52), neonatal overnutrition 
(NeoON) increased adult body weight (control [Ct]: 
286.6 ± 3.9 g, NeoON: 353.2 ± 5.3 g; P < 0.0001) and 
circulating leptin (Ct: 2.12 ± 0.19 ng/ml, NeoON: 
5.00 ± 0.07 ng/ml; P < 0.005). In contrast with our pre-
vious studies (52), insulin levels were also increased 
(Ct: 0.34 ± 0.03 ng/ml, NeoON: 0.51 ± 0.07 ng/ml; 
P < 0.05), while acylated ghrelin levels were decreased 
(Ct: 76.5 ± 8.1 pg/ml, NeoON: 50.2 ± 5.1 pg/ml; 
P < 0.02), with no change in total ghrelin (Ct: 
923.1 ± 107.3 pg/ml, NeoON: 879.4 ± 107.3 pg/ml) 
or the percentage of acylated ghrelin (Ct: 7.4% ± 1.1%, 
NeoON: 5.6% ± 0.8%). These differences are most 
likely due to fasting of the rats before sacrifice in the 
present study.
In NeoON rats, the hypothalamic mRNA levels 
for neuropeptide Y (NPY) were lower (Ct: 100% ± 12.2%, NeoON: 
37.4% ± 9.0%; P < 0.01) and proopiomelanocortin (POMC) levels 
higher (Ct: 100% ± 33.8%, NeoON: 359.7% ± 71.1%; P < 0.001), with 
no difference in cocaine- and amphetamine-regulated transcript 
(CART) (Ct: 100% ± 22.4%, NeoON: 82.9% ± 16.6%), Agouti-related 
peptide (AgRP) (Ct: 100% ± 14.6%, NeoON: 136.5% ± 23.1%), or 
LepR (Ct: 100% ± 11.3%, NeoON: 137.0% ± 5.6%) mRNA levels.
Astrocyte structural protein levels, number, and morphology. As pre-
viously reported (18) hypothalamic glial fibrillary acidic protein 
(GFAP) (Figure 1A; P < 0.01) and actin (Ct: 100% ± 7.8%, NeoON: 
196.3% ± 36.1%; P < 0.05) levels were increased in NeoON rats. The 
number and morphology of GFAP+ cells in the arcuate nucleus 
of NeoON rats were visually different from controls (Figures 1, B 
and C), and quantitative analysis indicated an increase in the mean 
number of astrocytes/area (Figure 1D; P < 0.05). NeoON rats also 
had more primary projections/GFAP+ cell (Figure 1E; P < 0.01), 
with no difference in mean projection length (Figure 1F). We previ-
ously demonstrated that intracerebroventricular (icv) leptin treat-
ment increases hypothalamic GFAP levels, but this is associated 
with longer projections of GFAP+ cells and no change in cell num-
ber or projections/cell (18). High-fat diet–induced (HFD-induced) 
weight gain results in hypothalamic gliosis and changes in glial 
coverage of neurons and vasculature (8–10). However, whether this 
is associated with an increase in the number of astrocytes remains 
to be determined. As leptin modifies astrocyte development (51, 
53), we analyzed whether NeoON increases leptin levels at an age 
when metabolic circuits are still developing. At P10, NeoON rats 
Figure 1
Modification of hypothalamic astrocytes in response 
to NeoON. (A) GFAP levels in the hypothalamus of 
rats from litters of 12 pups (control [Ct]) and litters of 4 
pups with NeoON. (B) Photomicrographs of immuno­
histochemistry for GFAP in the arcuate nucleus of (B) 
control and (C) NeoON rats. Morphological analysis 
demonstrated that in NeoON adults, there was an 
increase in the number of GFAP+ cells in the arcuate 
nucleus (D) and the number of primary projections/
GFAP+ cell (E), with no difference in the mean pro­
jection length (F). *P < 0.05; **P < 0.01; ***P < 0.001. 
Scale bars: 50 μm.
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weighed more (Ct: 22.4 g ± 0.1 g, NeoON: 24.7 g ± 0.2 g; P < 0.0001) 
and had higher circulating leptin levels (Ct: 3.97 ± 0.26 ng/ml, 
NeoON: 12.45 ± 3.03 ng/ml; P < 0.0001). Thus, this early rise in 
leptin could affect glial development and the number of hypotha-
lamic astrocytes in adulthood.
In the hippocampus, an area involved in eating behavior (54), 
GFAP levels were also increased by NeoON (Ct: 100% ± 6.7%; 
NeoON: 162.0% ± 18.8%; P < 0.005), while in the cerebellum, GFAP 
levels were unaffected (Ct: 100% ± 15.5%; NeoON: 105.7% ± 9.8%). 
In contrast to the hypothalamus, the increase in hippocampal 
GFAP was not associated with a change in the number of astro-
cytes (Ct: 15.4 ± 0.6 GFAP+ cells/field; NeoON: 15.9 ± 1.3 GFAP+ 
cells/field) or primary projections/astrocyte (Ct: 2.9 ± 0.6 projec-
tions/GFAP+ cells; NeoON: 2.9 ± 0.9 projections/GFAP+ cells), but 
with an increase in the mean projection length (Ct: 15.6 ± 2.1 μm; 
NeoON: 17.7 ± 0.8 μm; P < 0.01).
Vimentin levels were increased in the hypothalamus (Figure 2A; 
P < 0.01) and hippocampus (Figure 2B; P < 0.01) of NeoON rats. In 
the hypothalamus, this structural protein is expressed in tanycytes 
and immature and activated astrocytes, with vimentin immunore-
activity being primarily seen in tanycytes of NeoON rats (Figure 
2, C–H), with only occasional vimentin-reactive astrocytes being 
found (Figure 2F). This is similar to what was previously reported 
in response to leptin (18). However, in the hippocampus, vimentin 
immunoreactivity was found in astrocytes in both experimental 
groups (Figure 2, I and J). Vimentin levels were not affected in the 
cerebellum (Ct: 100% ± 11.2%; NeoON: 104.0% ± 21.2%).
Inflammatory markers in the hypothalamus of NeoON rats. We 
have previously reported an increase in the number of activated 
microglia in specific hypothalamic nuclei of NeoON rats (55). 
However, there was no change in levels of Iba1 (Ct: 100% ± 4.2%; 
NeoON: 101.7% ± 13.1%), a marker of total microglia, suggest-
ing that unlike astrocytes, the overall number of microglia is 
not affected. We also found no effect of NeoON on hypotha-
lamic TNFα (Ct: 100% ± 10.8%, NeoON: 86.2% ± 6.8%), IL6 (Ct: 
100% ± 26.3%, NeoON: 71.3% ± 9.8%), or IL1β (Ct: 100% ± 20.0%, 
NeoON: 75.4% ± 8.4%) mRNA levels, in agreement with previ-
ous studies (55), or in SOCS3 mRNA levels (Ct: 100% ± 12.8%, 
NeoON: 95.6% ± 17.4%). These results, together with the previ-
ously reported lack of activation of the IKKβ⁄NF-κB pathway in 
NeoON adults (55), indicate that overall hypothalamic inflam-
mation, as well as leptin resistance, does not exist. It should be 
taken into consideration that inflammatory processes could be 
restricted to specific nuclei (55) or develop with further weight 
gain. Moreover, in the absence of direct evidence for the genera-
tion of antiinflammatory cytokines, morphological changes in 
microglia may indicate an “alternate” phenotype and not neces-
sarily an inflammatory phenotype.
Glucose and glutamate transporter levels in response to NeoON. Glial 
cells are involved in glucose transport both into and within the 
brain and differentially express glucose transporters compared 
with neurons (25, 27, 28, 34–36). The mean levels of GLUT-1, 
expressed mainly in astrocyte endfeet surrounding blood vessels, 
and GLUT-2, expressed in astrocytes and tanycytes, were increased 
in the hypothalamus of NeoON rats (Figure 3A; P < 0.0001 and Fig-
ure 3B; P < 0.05, respectively). In contrast, levels of GLUT-3, which 
is expressed in neurons (34–36), were reduced (Figure 3C, P < 0.05).
Hypothalamic levels of the glutamate transporters GLAST 
(Figure 3D; P < 0.05) and both isoforms of GLT-1 (Figure 3E; 
GLT-1.75 P < 0.01 and GLT-1.51; P < 0.05) were higher in NeoON 
rats. Levels of GS, an astrocyte-specific enzyme essential for the 
glutamate/glutamine cycle (56), were also increased (Figure 3F; 
P < 0.0001), while GAD levels were decreased (Figure 3G; P < 0.05). 
Thus, the majority of astrocyte-specific proteins studied were 
Figure 2
Modification of vimentin levels and distribution by NeoON. Vimentin 
levels in the hypothalamus (A) and hippocampus (B) of rats from litters 
of 12 pups (control) and litters of 4 pups with NeoON. Photomicro­
graphs of immunohistochemistry for vimentin in the hypothalamus of 
control (C, E, and G) and NeoON rats (D, F, and H) and hippocampal 
astrocytes in control (I) and NeoON (J) rats. Arrows indicate vimentin­
positive astrocytes, **P < 0.01. 3V, third ventricle. Scale bars: 50 μm 
(C–F, I, J.); 20 μm (G and H).
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increased in NeoON rats, which could be directly related to the 
increased number of astrocytes. However, there was no change in 
the number of astrocytes/area in the hippocampus, but GLUT-1 
(Ct: 100% ± 7.3%; NeoON: 171.3% ± 30.9%; P < 0.05), GLUT-2 
(Ct: 100% ± 5.6%; NeoON: 161.7% ± 19.6%; P < 0.02), GLAST (Ct: 
100% ± 6.5%; NeoON: 130.6% ± 7.9%; P < 0.05), and GS (Ct: 100% ± 
9.7%; NeoON: 233.4% ± 37.6%; P < 0.005) were all higher in NeoON 
rats, indicating increased expression/cell. Levels of GLUT-3 (Ct: 
100% ± 6.4%; NeoON: 130.5% ± 17.2%), GLT-1.51 (Ct: 100% ± 
18.6%; NeoON: 144.1% ± 27.2%) and GLT-1.75 (Ct: 100% ± 12.6%; 
NeoON: 83.8% ± 8.3%) were not different.
In the cerebellum, there was no effect of NeoON on GLUT-1 
(Ct: 100% ± 6.9%; NeoON: 114.6% ± 7.5%), GLUT-2 (Ct: 100% ± 
13.0%; NeoON: 122.7% ± 6.7%), GLUT-3 (Ct: 100% ± 7.0%; NeoON: 
118.1% ± 20.1%), GS (Ct: 100% ± 8.4%; NeoON: 91.6 %± 6.9%), 
GLT-1.51 (Ct: 100% ± 6.9%; NeoON: 91.4% ± 17.1%), GLT-1.75 (Ct: 
100% ± 17.3%; NeoON: 83.8% ± 14.9%), or GLAST (Ct: 100% ± 7.7%; 
NeoON: 97.3% ± 9.7%)
Glial proteins and glucose and glutamate transporter levels in response to 
fasting. In contrast with being obese or overweight, fasting induc-
es a state of negative energy balance, suggesting that opposite 
effects on glial proteins and glucose and glutamate transporters 
might be observed. Fasting for 12 hours (12hfast) and 24 hours 
(24hfast) decreased both insulin (Ct: 1.01 ± 0.28 ng/ml, 12hfast: 
0.43 ± 0.15 ng/ml, 24hfast: 0.19 ± 0.01 ng/ml; P < 0.03) and 
leptin (Ct: 7.11 ± 0.43 ng/ml, 12hfast: 0.95 ± 0.18 ng/ml, 24hfast: 
1.32 ± 0.22 ng/ml; P < 0.0001) levels, as expected. However, similar 
to that observed in NeoON rats, hypothalamic GFAP levels were 
also increased with fasting (Figure 4A; P < 0.01), but vimentin was 
decreased (Figure 4B; P < 0.005). Likewise, GLUT-1 (Figure 4C; 
P < 0.005) and GLAST (Figure 4F; P < 0.001) also increased after a 
24hfast. Fasting increased GLUT-3 levels (Figure 4E, P < 0.01) and 
decreased GLUT-2 levels (Figure 4D; P < 0.01). There was no effect 
of fasting on either isoform of GLT-1 (GLT-1.51 Ct: 100% ± 4.5%, 
12hfast: 102.1% ± 4.9%, 24hfast: 109.5% ± 6.5%) and GLT-1.75 (Ct: 
100% ± 7.2%, 12hfast: 93.7% ± 6.4%, 24hfast: 106.5% ± 11.8%) or 
GS (Ct: 100% ± 4.6%, 12hfast: 98.2% ± 4.5%, 24hfast: 96.4% ± 8.9%).
Glucose and glutamate transporter levels in response to leptin. We previ-
ously reported that chronic icv leptin treatment increases hypo-
thalamic GFAP and vimentin levels (18), as found in NeoON rats. 
Figure 3
Changes in glucose and glutamate transporters in response to NeoON. (A) GLUT­1, (B) GLUT­2, (C) GLUT­3, (D) GLAST, (E) GLT­1, (F) GS, and 
(G) GAD levels in the hypothalamus of rats from litters of 12 pups (control) and litters of 4 pups with NeoON. *P < 0.05; **P < 0.01; ***P < 0.0001.
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Thus, we analyzed whether leptin could be involved in the changes 
observed in glutamate and glucose transporters in vivo. Chronic 
icv leptin treatment had no effect on hypothalamic GLUT-1 (Ct: 
100% ± 12.2%, leptin: 87.6% ± 12.8%), but reduced GLUT-2 (Fig-
ure 5A; P < 0.01), GLUT-3 (Figure 5B; P < 0.005), and GLAST 
levels (Figure 5C; P < 0.0001). There was no effect on either iso-
form of GLT-1 (GLT-1.75: Ct: 100% ± 6.6%, leptin: 108.7% ± 6.7%; 
GLT-1.51: Ct: 100% ± 2.5%, leptin: 94.6% ± 3.6%) or GS (Ct: 
100% ± 3.8%, leptin: 104.7% ± 7.8%).
In primary astrocyte cultures, GFAP levels increase after 24-hour 
exposure to leptin, similar to that observed with chronic icv leptin 
treatment (18); thus, further analysis of the direct effect of chron-
ic in vitro exposure to leptin was performed. No effect of leptin 
on GLUT-2 (Ct, 0 h: 100% ± 4.2%, Ct, 24 h: 101.4% ± 6.6%, leptin, 
24 h: 95.%3 ± 10.6%) or GS levels (Ct, 0 h: 100% ± 1.2%, Ct, 24 h: 
97.2% ± 5.3%, leptin, 24 h: 111.9% ± 11.0%) was seen, while GLUT-1 
was undetectable by Western blotting. However, leptin reduced 
GLAST (Figure 5D; ANOVA P < 0.0001) and GLT-1.51 levels (Fig-
Figure 4
Fasting­induced changes in glial 
proteins. (A) GFAP, (B) vimen­
tin, (C) GLUT­1, (D) GLUT­2, (E) 
GLUT­3, and (F) GLAST levels in 
the hypothalamus of adult male rats 
that were not fasted (control), fasted 
for 12 hours, or fasted for 24 hours. 
**P < 0.01; ***P < 0.001; #P < 0.005.
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ure 5E; ANOVA P < 0.0001), while the reduction in GLT-1.75 was 
not significant. This decrease in glutamate transporters was asso-
ciated with an increase in the levels of glutamate found in the cul-
ture medium after 24 hours of incubation with leptin (Figure 5F).
To determine how leptin affects membrane-associated GLAST 
levels (functional GLAST), the astrocyte cell line C6 was used in 
order to isolate sufficient membrane proteins. Leptin increased 
GFAP protein levels (Ct, 0 h: 100% ± 8.8%, Ct, 24 h: 102.4% ± 7.8%, 
leptin, 24 h: 141.0% ± 3.4%; ANOVA: P < 0.05) similar to as was pre-
viously shown for primary hypothalamic astrocyte cultures (18). 
Leptin also decreased overall GLAST levels (Figure 5G; ANOVA: 
P < 0.05), as seen in primary cultures, and in addition, decreased 
membrane-associated GLAST levels (Figure 5H; ANOVA: P < 0.05). 
Thus, chronic exposure to leptin both in vivo and in vitro reduces 
the glutamate captation capacity of astrocytes.
The astroglial response to leptin in vitro is time dependent, 
with GFAP levels decreasing at 1 hour and increasing by 24 
hours (18); thus, we determined how leptin affects glucose and 
glutamate transport at these time points. There was a significant 
interaction between leptin treatment and time on GLAST lev-
els (F2,22: 15.170; P < 0.001). At 1 hour, GLAST levels increased, 
while at 24 hours, there was a decrease (Figure 6A; P < 0.0001). 
This was coincident with a rapid leptin-induced increase in glu-
tamate uptake into hypothalamic astrocytes at 30 minutes, but 
a decrease in uptake at 24 hours (Figure 6B; P < 0.0005). This is 
also in accordance with the increase in glutamate in the culture 
medium at 24 hours (Figure 5F).
Leptin increased GLUT-2 levels at 1 hour with no effect at 24 
hours (Figure 6C). However, glucose uptake was decreased at 
1 hour and increased at 24 hours (Figure 6D; P < 0.0005). This 
leptin-induced increase in glucose uptake at 24 hours was not 
associated with an increase in overall GLUT-2 protein levels or 
GLUT-2 in the cell membrane or the mRNA levels of GLUT-2 (Ct, 
0 h: 100%, Ct, 24 h: 164.5% ± 50.6%, leptin, 24 h: 131.0% ± 42.6%), 
GLUT-1 (Ct, 0 h: 100%, Ct, 24 h: 136.1% ± 19.6%, leptin, 24 h: 
123.4% ± 21.2%), or GLUT-3 (Ct, 0 h: 100%, Ct, 24 h: 106.5% ± 10.1, 
leptin, 24 h: 104.3% ± 14.1%). These results suggest that glucose 
uptake may be modulated by leptin in the absence of alterations 
in glucose transporter expression.
Receptors for other circulating factors involved in glucose homeo-
stasis are also expressed in astrocytes in vitro. Insulin receptor (Ct, 
0 h: 100%, Ct, 24 h: 117.5% ± 5.6%, leptin, 24 h: 78.3% ± 10.1%) and 
Figure 5
Leptin­induced modifications in glucose and glutamate transporters. (A) Hypothalamic levels of GLUT­2, (B) GLUT­3, and (C) GLAST levels in 
adult male rats treated with leptin icv for 14 days (15 μg/d). (D) GLAST and (E) GLT­1 levels in primary hypothalamic astrocyte cultures treated with 
saline (control) or leptin (100 ng/ml) for 24 hours (ct24 and Lep24). (F) Relative glutamate levels in the culture medium of primary hypothalamic 
astrocyte cultures after treatment with either saline or leptin for 24 hours. (G) Total or (H) membrane GLAST levels in cultures of the astroglioma 
cell line C6 after treatment with leptin for 24 hours. **P < 0.01; ***P < 0.0001; #P < 0.005.
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glucagon receptor mRNA levels were not modulated by leptin, 
although the latter declined over time (Ct, 0 h: 100, Ct, 24 h: 
66.5 ± 6.5, leptin, 24 h: 52.2 ± 9.2%; F2,8: 14.308; P < 0.005). We were 
unable to detect expression of the ghrelin receptor in these cultures 
by RT-PCR. How these other metabolic hormones modulate astro-
cyte functions remains to be determined.
To examine how leptin directly affects glucose transporters in 
neurons, the hypothalamic neuronal cell line RCA6 was used. This 
cell line expresses the LepR and responds to leptin in a dose-depen-
dant manner (data not shown). Leptin had no effect on GLUT-1 
levels (Ct, 0 h: 100% ± 0.6%, Ct, 24 h: 131.0% ± 15.3%, leptin, 24 h: 
162.3% ± 24.1%), but decreased GLUT-3 levels (Ct, 0 h: 100% ± 2.2%, 
Ct, 24 h: 90.4% ± 4.2%, leptin, 24 h: 67.0% ± 11.1%; P < 0.04). GLUT-2 
was not detectable by Western blotting in this cell line.
Effect of maternal HFD. Given that early neonatal nutrition and 
leptin modulate glial proteins and functions, we studied how 
maternal nutrition modifies astrocyte morphology and activity 
of POMC neurons. At 24 days of age, there was no effect of the 
maternal diet on body weight (Ct: 11.9 ± 0.5 g, maternal HFD 
[MHFD]: 11.8 ± 0.5 g) or NPY mRNA levels (Ct: 100% ± 8.5%, 
MHFD: 96.8% ± 4.6%); however, POMC mRNA levels were sig-
nificantly increased (Ct: 100% ± 4.7%, MHFD: 182.9% ± 28.9%; 
P < 0.05) While glycemia did not differ statistically (144.5 ± 10.3 
mg/dl, 125.0 ± 14.8 mg/dl), insulin levels were significantly ele-
vated (Ct: 0.63 ± 0.1 ng/ml, MHFD: 1.28 ± 0.3 ng/ml; P < 0.05).
Importantly, MHFD increased glia coverage of POMC neurons 
in the hypothalamus (Figure 7, A–C). This was coincident with a 
decrease in the baseline frequency of miniature inhibitory postsyn-
aptic currents (Figure 7D), with no change in miniature excitatory 
postsynaptic current frequency. In addition, POMC neurons from 
HFD mothers responded to a reduction in glucose concentration 
by a decrease in action potential frequency, while no change was 
found in controls (Figure 7E).
Discussion
Glial cells have come to the forefront in obesity investigation (6, 
8, 10, 11, 16, 57) partially due to recent reports showing hypotha-
lamic inflammation and glial activation in response to high-fat 
intake and metabolic factors (8, 9, 11, 16). However, increased 
hypothalamic GFAP levels (18) and microglial activation (55) are 
found in overweight NeoON rats raised on a normal diet, implying 
that HFD is not the only metabolic perturbation to which these 
cells respond. The NeoON-induced changes in GFAP ware asso-
ciated with an increase in the number of astrocytes and of their 
projections in the arcuate nucleus; however, there was little indica-
tion of gliosis or astrocyte activation, as these glial cells were only 
Figure 6
Leptin­induced modifications in glutamate and 
glucose uptake by hypothalamic astrocytes. 
(A) Levels of GLAST in primary hypothalamic 
astrocyte cultures treated with saline (control) 
or leptin (Lep, 100 ng/ml) for 1 or 24 hours. (B) 
Glutamate uptake in hypothalamic astrocytes 
in vitro in response to leptin after 30 minutes. 
(C) Levels of GLUT­2 in primary hypothalamic 
astrocyte cultures treated with saline (control) 
or leptin (Lep, 100 ng/ml) for 1 or 24 hours. (D) 
Glucose uptake in hypothalamic astrocytes in 
vitro in response to leptin after 1 or 24 hours. 
#P < 0.0005.
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occasionally found to be vimentin positive and no increase in the 
expression of TNFα, IL1β, or IL6 was detected. In contrast, other 
glial proteins were markedly affected.
Each astrocyte defines a functional domain in the brain (2) such 
that an increase in the number of hypothalamic astrocytes changes 
the local anatomical structure and functionality; this could have 
important effects on neuronal circuits controlling metabolism. 
The upregulation of GLUT-1 and -2, GLAST, GLT-1, and GS in 
NeoON rats may be directly related to the greater number of glial 
cells, but could also result from changes in expression level per cell. 
Regardless of the specific mechanism, the overall hypothalamic 
capacity to transport and metabolize glucose and glutamate is 
increased. Hence, these factors and possibly other metabolic sig-
nals that are transported, produced, or processed by astrocytes and 
tanycytes may be perceived differently in the hypothalamus of these 
overweight rats. For example, modification of GLUT-2 in hypotha-
lamic astrocytes affects central glucose sensing (32) and NeoON 
have increased hypothalamic GLUT-2 levels, with an altered glu-
cose tolerance response and an increase in carbohydrate intake (58).
Transport of neurotransmitters and glucose by astrocytes 
governs the composition of the extracellular space surround-
ing neurons, thus directly influencing neuronal electrical activ-
ity and glucose-sensing capacity (30, 59, 60), both of which are 
affected by early changes in nutritional status. Glial coverage of 
POMC neurons in the arcuate nucleus was increased in offspring 
of mothers fed a HFD, and this was associated with a decrease in 
miniature inhibitory postsynaptic current (mIPSC) frequency. 
Moreover, glucose sensing was affected, as POMC neurons from 
these mice responded differently to a change in glucose concen-
tration. Decreased inhibitory electrical activity was in accordance 
with the rise in POMC mRNA levels, which together indicate that 
even at this early stage of development, this system is sensitized to 
metabolic signals and attempting to compensate for the maternal 
high-fat exposure. However, it remains to be determined how these 
modifications in electrical activity and glucose responsiveness of 
POMC neurons are involved in the long-term metabolic changes 
reported after MHFD exposure.
Some of the long-term metabolic outcomes due to changes 
in early nutritional status have been attributed to affectation of 
leptin levels during critical developmental periods. Leptin is impli-
cated in brain progenitor cell proliferation and astrocyte differen-
tiation (51, 53); thus, the hyperleptinemia at P10, a critical period 
for development of hypothalamic circuits (61), could underlie 
the increase in astrocytes in NeoON rats. The hyperleptinemia 
in adult overweight rats could also increase GFAP and vimentin 
expression, but leptin treatment in adult rats was not found to 
modify the number of astrocytes (18). Of note, HFD-induced obe-
sity is associated with hypothalamic glial activation, as shown by 
increased GFAP levels (8, 9, 11, 16), increased astrocytic coverage 
of neurons and capillaries (9), and activation of microglia (11), but 
no increase in the number of astrocytes has been reported to date. 
Whether gliosis and hypothalamic inflammation progress with 
Figure 7
Effects of maternal diet on glial 
coverage and glucose sensitiv­
ity of POMC neurons. Electron 
micro graphs of POMC neurons in 
the arcuate nucleus of 24­day­old 
mice from mothers on a control 
(A) or MHFD diet (B). Glial cover­
age is outlined in green. There was 
a significant increase in the mean 
glial coverage of POMC neurons in 
MHFD mice (C). The frequency of 
resting mEPSCs was not affected 
by MHFD, but mIPSC frequency 
was significantly decreased (D). 
Lowering glucose concentration 
decreased action potential frequen­
cy in POMC neurons from MHFD 
mice, but had no effect on control 
mice (E). *P < 0.05, **P < 0.01, 
***P < 0.001. Scale bar: 500 nm.
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increased weight gain on a normal diet remains to be determined, 
but it is conceivable that hypothalamic inflammation in response 
to HFD involves more than one process, including those due to 
metabolic and/or toxic effects of the diet and those resulting from 
weight gain and its other associated complications. Furthermore, 
the early metabolic environment could determine astrocyte devel-
opment, including cell number, while later metabolic or dietary 
modifications may preferentially affect glial functions.
One fundamental function of astrocytes is to control the extra-
cellular concentrations of glutamate and GABA (2, 22, 23, 37–40), 
with the balance of the activity of these 2 neurotransmitters within 
the hypothalamus being crucial in determining metabolic output 
(62). The fasting-induced rise in GLUT-1, GLUT-3, GLAST, and 
GFAP is in concordance with increased neuronal activity and glu-
tamate uptake by astrocytes, as glutamate uptake into astrocytes 
rises with increased glutamate concentrations in the synaptic cleft 
(63, 64) and glucose uptake is stimulated with increased neuronal 
activity (65, 66). Moreover, GFAP is essential for retaining GLAST 
in the cell membrane (67). Fasting activates AgRP neurons (68) via 
increased NMDA receptor–dependent excitatory tone (69) to stim-
ulate appetite and food-seeking behavior, while glutamate input to 
POMC neurons does not appear to be critical for fasting responses 
(69). Glutamate release in the ventromedial hypothalamus is also 
important for the prevention of hypoglycemia during fasting (70). 
Although glutamate can directly stimulate its own reuptake into 
astrocytes to impede excitotoxicity (71), fasting-induced metabolic 
changes, such as changes in leptin levels, may also participate in 
this process. Our results indicate that leptin directly modulates glu-
tamate uptake in astrocytes in a time-dependant manner, stimu-
lating a rapid increase that is downregulated with chronic exposi-
tion. Thus, the decrease in circulating leptin after 12 and 24 hours 
of fasting could result in increased GLAST levels, although other 
metabolic signals may also be involved.
The rise in GLUT-1 in response to fasting is reported to partici-
pate in glucose sensing, glycemia control, and neuroprotection 
against hypoglycemia (72, 73). Decreased GLUT-2 stimulates appe-
tite (33), which is coherent with the observed decline caused by 
fasting found here, while the increase in NeoON rats would serve 
as a signal to decrease food intake. Leptin modulates glucose trans-
porters in different tissues (74–76), and this cytokine decreased 
with fasting and increased in NeoON rats. However, chronic 
icv treatment decreased both hypothalamic GLUT-2 and -3, 
but had no effect on GLUT-1 levels, and we found no evidence 
of a direct effect of chronic leptin treatment on GLUT-1, -2, or -3 
mRNA or GLUT-2 protein levels in astrocytes. In contrast, leptin 
decreased GLUT-3 in neurons in vitro. In fasted individuals, leptin 
levels decreased and glucose levels increased, with the inverse 
occurring with feeding; thus, under normal conditions, leptin may 
be another signal indicating nutrient availability directly to neu-
rons and regulating their glucose uptake. However, the decrease in 
GLUT-3 expression in this neuronal cell line could also indicate a 
leptin-induced decrease in activity and thus glucose utilization.
Although no in vitro changes in glucose transporter levels were 
found in response to leptin after 24 hours, it stimulated glucose 
transport in astrocytes, and this was preceded by a rapid decrease in 
uptake. We have previously found the effects of leptin on astrocytes 
to be biphasic, rapidly reducing GFAP levels both in vivo and in vitro, 
which is then followed by an increase at 24 hours (18). The leptin-
induced changes in glucose uptake did not correspond to modifica-
tions in GLUT-2 mRNA, total protein, or membrane protein levels; 
indeed, although glucose uptake decreased at 1 hour, total GLUT-2 
levels increased. Other glucose transporter forms are most likely 
involved in this response, and further studies are required to deter-
mine the physiological implications of this phenomenon.
Leptin-induced glutamate uptake was also biphasic and cor-
responded to the observed changes in GLAST. The rapid rise in 
glutamate captation indicates that leptin could reduce the stimu-
latory effects of glutamate at nearby synapses, emphasizing the 
importance of astrocyte number and morphology and their inter-
actions with neurons. Whether chronic exposure to increased 
leptin levels, as frequently occurs in overweight or obese subjects, 
reduces the ability of astrocytes to correctly modulate glutamate 
levels in the synaptic cleft or whether this is an adaptational mech-
anism remains to be determined.
Astrocytes were modified by NeoON in an anatomically specific 
manner, similar to that induced by leptin (18). Glial proteins were 
upregulated in the hippocampus, but not in the cerebellum, sug-
gesting that the effects could be related to metabolic control, as 
the hippocampus is involved in food-seeking and food-memory 
behaviors (54, 77), with leptin targeting this brain area and mod-
ulating these effects (77). Moreover, HFD modifies glutamate 
uptake and metabolism in the hippocampus (78). In contrast with 
the hypothalamus, in the hippocampus, vimentin is expressed in 
astrocytes, with its levels increasing with age; this is suggested to 
impede neurogenesis (79). Further investigation into the anatom-
ically distinct responses and functions of glial cells could prove 
prosperous in identification of new targets for obesity control.
Multiple metabolic factors exert at least part of their central effects 
through hypothalamic astrocytes and tanycytes. For example, these 
glial cells express type II iodothyronine 5′-deiodinase (DII), an 
enzyme required for T3 production, and mediate central thyroid 
hormone effects. DII levels are modulated by fasting and implicated 
in T3 effects on NPY/AgRP neuron responses to fasting (6, 15, 80). 
Moreover, leptin’s inhibitory effects on feeding are partially mediated 
through apoE signaling in the hypothalamus, and in the CNS, apoE 
is produced by astrocytes (81). Thus, it is clear that glia respond to 
numerous metabolic signals, indicating that modifications in their 
number or function in the hypothalamus would have dramatic 
effects on metabolic responses. Astrocytes express receptors for glu-
cagon and insulin, and these receptors were not modified by leptin 
treatment. How the ligands for these receptors affect astrocyte func-
tion in metabolic control remains to be addressed.
Astrocytes are clearly involved in metabolic control and are 
most likely involved in the pathogenesis of obesity. Here, we dem-
onstrate that physiological changes in metabolic status as well as 
increased body weight on a normal diet substantially affect glial 
cells. Some of these effects are through leptin, as it not only mod-
ulates glial morphology and activation, but has direct effects on 
glutamate and glucose uptake by hypothalamic astrocytes, which 
would directly modulate local synaptic circuits and neuronal activ-
ity. Hence, the participation of astrocytes and most likely tany-
cytes in metabolic control appears to be multiform, and these cells 




Wistar rats were bred in our in-house facilities. On the day of birth, cross-
fostering was employed to produce litters of 4 pups (NeoON) or 12 pups/
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dam for controls. After weaning on P21, rats were placed at 4 rats per cage 
under constant temperature (20–22°C), with lights on from 0730 to 1930 
hours. They were given free access to normal rat chow and tap water.
Rats were killed on P90 between 900 and 1100 hours after a 12-hour 
fast. Thirteen rats per group were sacrificed by decapitation. Trunk blood 
was collected in cooled tubes, allowed to clot, centrifuged, and stored at 
–80°C. The brains were removed and rapidly frozen on dry ice and stored 
at –80°C. Seven rats per group were perfused transcardially with phos-
phate-buffered 4% paraformaldehyde (pH 7.4) under pentobarbital anes-
thesia (1 mg/kg). The brains were postfixed overnight at 4°C and then 
stored in cryoprotection solution (30% sucrose, 30% ethylene glycol in 
phosphate buffer) at –20°C.
To determine whether this experimental paradigm modulates circulat-
ing leptin levels during early stages when leptin imprinting on the meta-
bolic system is thought to occur, one group of rats (n = 6) was weighed and 
sacrificed by decapitation at P10. Trunk blood was collected and handled 
as described above.
Fasting
Adult male Wistar rats (250–300 g; n = 6/group) were killed between 0900 
and 1100 hours by decapitation after 12 or 24 hours of fasting or without 
fasting. Brains and trunk blood were collected as described above.
Chronic leptin treatment during adulthood
Adult male Wistar rats (250–300 g; n = 6/group) were anesthetized with 
2.5% Fluothane (AstraZeneca Farmacéutica SA), and a minipump (Alzet; 
Durect Co.) delivering 15 μg/d leptin (Sigma-Aldrich) or saline for 14 
days was implanted in the left lateral ventricle (–0.3 mm anteroposterior, 
1.1 mm lateral from bregma). Rats were weighed every 2 days until killed 
between 0900 and 1100 hours by decapitation after the 14th day of treat-
ment. Brains and trunk blood were collected as described above. The meta-
bolic changes observed in these animals have been previously reported (18).
MHFD
For electron microscopy and electrophysiology studies, C57BL/6 mice 
that express GFP under the POMC promoter (Jackson Laboratory) were 
employed. Female mice (8 weeks of age) were given free access to either a 
low-fat diet (3.3 Kcal/g, 59.8% carbohydrate, 28% protein, 12.1% fat; Purina 
Lab Chow 5001; Ralston Purina Co.) or HFD (4.75 Kcal/g, 35% carbohy-
drate, 20% protein, 45% fat; Purina Lab Chow D12451; Ralston Purina Co.) 
for 6 weeks before being placed with normal male mice. During gestation 
and lactation, they were maintained on their respective diets. On P21, mice 
were weaned and given normal rat chow ad libitum until sacrificed on P24.
In vitro studies
Primary astrocyte cultures. Two-day old male Wistar rats were decapitated 
and the diencephalon removed under sterile conditions and triturated in 
DMEM F-12 (Gibco; Invitrogen) containing 1% penicillin-streptomycin 
(Gibco; Invitrogen). The suspension was centrifuged and the pellet resus-
pended in DMEM F-12 plus 10% FCS (Linus) plus 1% antibiotics. Cells 
were grown in this culture medium in 75 cm3 culture flasks at 37°C and 5% 
CO2. On the ninth day, the flasks were placed in a 37°C shaking incubator 
(SI-300, Jeoi Tech; Medline Scientific) at 280 rpm for 16 hours. The cells 
were then harvested (0.05% trypsin/EDTA solution; Biochrom AG), resus-
pended in DMEM F-12 plus 10% FCS plus 1% antibiotics, and centrifuged 
for 5 minutes at 233.6 g. Cells were seeded at a concentration of 217,500 
cells/ml in culture plates previously treated with poly-l-lysine hydrobro-
mide (10 μg/ml; Sigma-Aldrich) and grown for 24 hours. The medium was 
changed to DMEM F-12 plus 1% antibiotics (without FCS), and 24 hours 
later, the same medium plus either 100 ng/ml of recombinant rat leptin 
(National Hormone and Pituitary Program) or vehicle was added. Cells 
were collected at 1 and/or 24 hours. In each experiment, treatments were 
done in triplicate; each experiment was repeated 3 to 6 times (n = 3 to 6).
Glial cell line C6. Stock cultures of the astrocytoma cell line C6 were a 
gift of L.M. García-Segura (Cajal Institute). Cells (1 × 106 cells/100 mm 
culture dish) were grown in RPMI (Biochrom) with 2.0 g/l NaHCO3, 
without phenol red, supplemented with 10% FCS, 100 U/ml penicillin-
streptomycin, and glutamine (200 mM), and maintained at 37°C and 5% 
CO2 for 72 hours. They were then maintained for 48 hours in differen-
tiation medium (RPMI supplemented with 2.0 g/l NaHCO3, 100 U/ml 
penicillin-streptomycin, glutamine [200 mM] and cAMP [100 mM]) with-
out FCS. Subsequently, the cells were treated with leptin at a concentra-
tion of 100 ng/ml or vehicle (saline) for 24 hours. Each treatment was 
done in triplicate and the experiment repeated 3 times (n = 3).
Hypothalamic neuronal cell line RCA-6
Stock cultures of the hypothalamic cell line RCA-6 (82), a gift of I. Torres-
Alemán (Cajal Institute), were grown in 100-mm culture dishes in DMEM 
without phenol red supplemented with 10% FCS, 100 U/ml penicillin-
streptomycin, and glutamine (200 mM) and maintained at 37°C and 5% 
CO2. Cells (2 × 105) were plated in 60-mm culture dishes for 72 hours in 
DMEM containing 10% FCS and then in DMEM-Ham’s F12 (1:1) without 
FCS, but containing 1.2 g/l NaHCO3, 15 mM HEPES, and supplemented 
with 0.1 mg/ml transferrin, 10–5 M putrescine, 2 × 10–8 M progesterone, 
10–7 M corticosterone, 10–5 M T3, 1 μg/ml arachidonic acid, and 2 × 10–8 
M Na2SeO3. Cultures were maintained for 48 hours in this differentiation 
medium without FCS and then treated with leptin at a concentration of 
10 ng/ml or vehicle for 24 hours. Each treatment was done in triplicate and 
the experiment repeated 3 times (n = 3).
Dose-response curves were performed in each cell type to determine the 
appropriate dose of leptin to be used. The lowest dose with the maximum 
effect was selected in each case.
Leptin and insulin ELISAs. Serum leptin and insulin levels were measured 
by ELISA following the manufacturer’s instructions (Linco Research). The 
lower limits of detection for the leptin and insulin assays were 0.04 and 
0.2 ng/ml, respectively. The intra-assay variation was 2.2% for leptin and 
1.9% for insulin, and the inter-assay variation was 3.4% for leptin and 7.6% 
for insulin. All samples were run in duplicate and within the same assay 
for all analyses.
Total and acylated ghrelin radioimmunoassays. Total and acylated ghrelin were 
measured by radioimmunoassay (RIA) following the manufacturer’s instruc-
tions (Linco Research). The sensitivity of the method was 93 pg/ml for both 
assays, and the intra- and inter-assay coefficients of variation were 6.4% and 
16.3% for total ghrelin and 7.4% and 13.4% for acylated ghrelin, respectively.
Glutamate concentrations. After incubation of primary hypothalamic astro-
cyte cultures with leptin or vehicle for 24 hours as described above, 1 ml 
of medium was removed from each culture and lyophilized (n = 3 inde-
pendent experiments). Glutamate detection was performed following the 
manufacturer’s instructions (BioVision).
Glucose uptake. [3H]-2-deoxy-glucose ([3H]-2-DG) uptake experiments 
were conducted as previously described (83), with some modifications.
The assay was initiated by replacing the culture medium with assay buffer: 
NaCl (113 mM), KCl (3 mM), KH2PO4 (1.2 mM), MgSO4 (1.2 mM), CaCl2 
(2.5 mM), NaHCO3 (25 mM), glucose (5.5 mM), and HEPES (10 mM) and 
washed (5 minutes). Astrocytes (25,000 in P96 plates, 100 μl) were either 
treated with leptin (100 ng/ml) for 24 hours or added for 10 minutes dur-
ing the preincubation period and maintained during the incubation. Assay 
buffer containing [3H]-2-DG (100 nM final concentration; specific activity 
60.0 Ci/mmol; American Radiolabeled Chemicals Inc.) was added, and the 
cells were incubated for an additional 60 minutes at 37°C in a shaking 
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incubator. Uptake was terminated by washing the cells 4 times for 3 min-
utes with ice-cold assay buffer. The cells were lysed with 120 μl 0.1 N NaOH 
scraped and maintained in a microplate shaker for 1 hour; an aliquot of 
100 μl was counted in a scintillation counter. Blanks that were similarly 
processed but incubated at 0°C accounted for 20% of the radioactivity 
in control cultures, and this was subtracted from all measurements. All 
experiments were performed in triplicate and using astrocyte cultures from 
at least 5 different male pups.
Glutamate uptake. Glutamate uptake was performed according to the 
method described by Flott and Seifert (84) with the modifications reported 
by Fernández-Tomé et al. (85). In preliminary experiments, the appro-
priate cell density was selected. Accordingly, astrocytes were plated at a 
density of 25,000 cells in 96-well plates (100 μl). In brief, cultures were 
washed (two 5-minute washes and one 10-minute wash) with warm (37°C) 
HEPES sucrose medium (HSM) (20 mM HEPES, pH 7.4, adjusted with 
KOH, isosmotic at 310 mosM by sucrose). Cultures were preincubated for 
10 minutes at 37°C in a shaking incubator in incubation buffer (28 mM 
HEPES, 150 mM NaCl, pH 7.4, adjusted with Tris base isosmotic at 310 
mosM by sucrose). Astrocytes were either treated with leptin (100 ng/ml) 
for 24 hours or added for 10 minutes during the preincubation period. 
After that, [3H]-Glu (10 nM final concentration; specific activity 30.0 Ci/
mmol; American Radiolabeled Chemicals Inc.) in 50 μM cold glutamate 
(in incubation buffer) was added to the cells and further incubated for 20 
minutes. Plates were washed (four 3-minute washes) with ice-cold HSM. 
The cells were lysed with 120 μl 0.1 N NaOH, scraped, and maintained 
in a microplate shaker for 1 hour; an aliquot of 100 μl was counted in a 
scintillation counter. Blanks that were similarly processed but incubated 
at 0°C accounted for 20% of the radioactivity in control cultures, and this 
was subtracted from all measurements. All experiments were performed in 
triplicate and using astrocyte cultures from at least 5 different male pups.
Protein extraction. Hypothalami were isolated on ice using the following 
boundaries: an anterior cut was made at the level of the optic chiasm, a 
posterior coronal section anterior to the mammillary bodies, 2 sagittal cuts 
parallel to the lateral ventricles, and a dorsal horizontal cut at the level of 
the anterior commissure. Tissue was homogenized on ice in RIPA lysis buf-
fer (50 mM NaH2PO4, 100 mM Na2H2PO4, 0.1% SDS, 0.5% NaCl, 1% Triton 
X-100) with 5 mg/ml sodium deoxycholate, phenyl-methane-sulfonylfluo-
ride (1 mM), and a cocktail of EDTA-free protease inhibitors (Roche Diag-
nostics). The lysates were incubated overnight at –80°C and centrifuged at 
14,000 g for 10 minutes at 4°C; the supernatant was transferred to a new 
tube to be stored at –80°C until assayed. Total protein concentration was 
determined by the method of Bradford (Bio-Rad Laboratories).
The RCA-6 cultures were processed using the above lysis buffer, while a 
lysis buffer containing 25 mM HEPES, 150 mM KCl, 2 mM EDTA, 0.1% 
Igepal, 1 mM PMSF, 10 μM benzamidine and leupeptin, and 0.5 mM 
DTT was used for primary astrocyte cultures. The samples were frozen 
and stored at –80°C for 24 hours. They were then centrifuged for 20 min-
utes at 21,200 g (4°C) and the supernatant removed. Protein from RCA-6 
neurons was stored at –80°C. The supernatant from astrocyte cultures 
was removed, frozen, lyophilized, and then resuspended in 40 μl sterile 
water and stored at –80°C.
Cell membrane isolation. Plasma membrane proteins isolation was per-
formed by using Plasma Membrane Qproteome kits (QIAGEN) following 
the manufacturer’s instructions and starting with 107 cells per column. 
Briefly, cells were lysed and centrifuged for 20 minutes at 15,600 g at 4°C. 
A sample of the total protein fraction (50 μl) was collected, lyophilized, 
resuspended in distilled water, and stored at –80°C. The binding ligand 
product supplied by the manufacturer was added to the samples and incu-
bated at 4°C for 60 minutes with continuous mixing. Equilibrated Strep-
Tactin magnetic beads were added to the remaining total protein fraction 
and incubated for 60 minutes at 4°C with continuous mixing. Membrane 
proteins were eluted from the magnetic beads with the supplied buffer 
and the proteins precipitated with acetone. The pellet was reconstituted in 
15 μl distilled water.
Western blotting. Proteins were resolved on a 10% SDS-polyacrylamide 
gel under denaturing conditions, electro-transferred to PVDF membranes 
(Bio-Rad), and the transfer efficiency determined by Ponceau red dyeing. 
Membranes were blocked and incubated overnight at 4°C under agitation, 
with the primary antibody at a concentration of 1:1000 unless otherwise 
stated. Primary antibodies included the following: anti-GFAP and anti-
vimentin (Sigma-Aldrich); anti-PCNA (Signet Laboratories); anti–GLT-1 
(Affinity BioReagents); anti–GLUT-1, anti–GLUT-2, anti–GLUT-3, and 
anti-GLAST (Alpha Diagnostic International); anti-GS (USBiological); 
anti-Iba1 (WAKO Chemicals); anti-GAD (Millipore); and anti-GAPDH 
(AnaSpec). Secondary antibodies conjugated with peroxidase were from 
Pierce Biotechnology. Bound peroxidase activity was visualized by chemi-
luminescence (PerkinElmer Life Science) and quantified by densitometry 
using a Kodak Gel Logic 1500 Image Analysis system and Molecular 
Imaging Software, version 4.0. All blots were rehybridized with GAPDH 
to normalize samples to control values on each gel. See complete uned-
ited blots in the supplemental material (available online with this article; 
doi:10.1172/JCI64102DS1).
RNA preparation and quantitative real-time PCR
Total RNA was extracted from the hypothalamus or cell cultures according 
to the Tri-Reagent protocol, and cDNA was then synthesized from total RNA 
by using a high-capacity cDNA reverse transcription kit (Applied Biosystems).
Hypothalamic AgRP (Rn01431703), POMC (Rn00595020), NPY 
(Rn01410145), CART (Rn00567382), LepR (Rn01433205), IL6 (Rn01410330), 
IL1β (Rn00580432), TNFα (Rn01525859), and SOCS3 (Rn00585674) mRNA 
levels were assessed by quantitative real-time PCR using assay-on-demand 
kits (Applied Biosystems). In cell cultures, GLUT-1 (Rn01417099), GLUT-2 
(Rn00563565) GLUT-3 (Rn00567331), GLUT-4 (Rn00562597), glucagon 
receptor (Rn00597158), ghrelin receptor (Rn00821417), and insulin receptor 
(Rn00567670) were used. TaqMan Universal PCR Master Mix (Applied Bio-
systems) was used for amplification according to the manufacturer’s proto-
col in an ABI PRISM 7000 Sequence Detection System (Applied Biosystems). 
Values were normalized to the housekeeping gene phosphoglycerate kinase 1 
(PGK-1) (Rn00821429). According to the manufacturer’s guidelines, the 
ΔΔCT method was used to determine relative expression levels. Statistics 
were performed using ΔΔCT values (86).
Electron microscopy. The mice were perfused (4% paraformaldehyde, 0.1% 
glutaraldehyde, and 15% picric acid in phospate buffer), and their brains 
were processed for immunolabeling for GFP for electron microscopy stud-
ies. Ultrathin sections were cut on a Leica Ultra-Microtome, collected on 
Formvar-coated single-slot grids, and analyzed with a Tecnai 12 Biotwin 
electron microscope (FEI). The analysis of synapse number was performed 
in an unbiased fashion as described elsewhere (14, 15, 17, 18, 22, 23).
Quantification of astrocytic coverage on POMC cells. The analysis of the astro-
cytic coverage of the cell membrane of labeled POMC cells was performed 
using ImageJ. Electron microscopy photographs (×11,500) were used to 
measure the perimeter of each POMC cell analyzed and the amount of 
membrane covered by astrocytes (in nanometers). The results are reported 
as astrocyte coverage/perimeter POMC cell.
Immunohistochemistry. Coronal brain sections (40 μm) were cut on a vibra-
tome (Leica VT1200S; Leica Biosystems Nussloch GmbH) and stored in 
cryoprotection solution at –20°C. Immunohistochemistry for GFAP and 
vimentin was performed as previously described (18). Six sections/animal 
distributed from –2.3 to –3.3 mm from the bregma (87) containing both 
the arcuate nucleus and hippocampus were analyzed. Images from 15 
research article
 The Journal of Clinical Investigation   http://www.jci.org   Volume 122   Number 11   November 2012 3911
Action potential threshold and spike frequency adaptation were examined 
as described in our previous papers (6, 17).
Miniature PSCs. Miniature excitatory postsynaptic currents (mEPSCs) 
were recorded under voltage clamp (held at –60 mV) in the presence of 
TTX (1 μM) and bicuculline (30 μM). mEPSCs were verified by being 
blocked with CNQX (10 μM) and AP-5 (50 μM). mIPSCs were recorded 
under voltage clamp (held at –60 mV) in the presence of TTX (1 μM), 
CNQX (10 μM), and AP-5 (50 μM), which were verified by being blocked 
with bicuculline (30 μM). To examine statistical significance of change in 
mPSC frequency in different conditions, Student’s t test and ANOVA were 
used to compare 2 or more groups of data, respectively. The Kolmogorov-
Smirnov test was used to evaluate the significance of change in the ampli-
tude of miniature postsynaptic currents.
Statistics
All data are presented as mean ± SEM. A 2-tailed Student’s t test was used 
for comparison between 2 groups and 1-way ANOVA for more than 2 
groups. Scheffe’s F test was employed for post-hoc analysis. All Western 
blotting results are reported as the percentage of the control value. P < 0.05 
was considered significant.
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rectangular fields of the arcuate nucleus and hippocampus correspond-
ing to an area of 19.5 mm2 in each section were captured at ×40 by using 
a digital camera. The number of GFAP immunoreactive (GFAP+) cells per 
field, the number of projections per cell, and the mean projection length 
were determined using Image-Pro Plus software (version 5.0 for Windows; 
Media Cybernetics Inc). All morphometric analyses were performed with-
out previous knowledge of the experimental group from which the sec-
tions were obtained.
Electrophysiology
Mice were anesthetized with isoflurane and killed by decapitation. The 
brain was gently removed from the skull and chilled in 4°C artificial 
cerebrospinal fluid (containing NaCl [126 mM]; KCl [2.5 mM]; MgCl2 
[1.2 mM]; CaCl2.2H2O [2.4 mM]; NaH2PO4.H2O [1.2 mM]; NaHCO3 
[21.4 mM]; glucose levels varied between 2.5 and 11.1: Krebs) that 
was saturated with 95% O2/5% CO2. Coronal slices (180 μm) were cut 
through the full extent of the arcuate nucleus/lateral hypothalamus. 
Slices were maintained for 1 hour at 35°C in 95% O2/5% CO2-saturated 
ACSF prior to recordings. We routinely obtained 6 usable slices contain-
ing GFP neurons from each mouse. After recovery for 1 hour, the slices 
were placed on the stage of the upright, hybrid fluorescence/infrared 
microscope with long working distance objectives (Olympus BX51WI), 
and the presence of florescent cells was verified. Fluorescence filter sets 
appropriate for Sapphire FP, cyan FP, and GFP (Chroma Technology 
Corp.) were used to confirm cell fluorescence. The slices are perfused 
with oxygenated Krebs (35°C). Using established criteria, an appropri-
ate healthy, fluorescent cell was visually selected, and a patch electrode 
(2–2.5 megaOhm resistance) advanced onto the surface of the cell by a 
piezo-electric drive. For measurements of membrane potential and glu-
tamatergic EPSCs, the patch electrode contained K gluconate (128 mM); 
HEPES (10 mM); EGTA (1 mM); KCl (10 mM); MgCl2 (1 mM); CaCl2 
(0.3 mM); {Mg}-ATP (5 mM); and {Na}GTP (0.3 mM); for measurements 
of GABAergic IPSC frequency, it contained CsCl (140 mM); Hepes (10 
mM); MgCl2 (5 mM); Bapta (1 mM); {Mg}-ATP (5 mM); and {Na}GTP 
(0.3 mM). The junction potential between the intracellular electrode and 
the bath solution was manually balanced immediately prior to seal for-
mation. A seal-test program (part of Axograph 4.9 software suite; Axon 
Instruments) was used to follow seal formation. Once the pressure in 
the electrode was released, a seal onto the cell began to form. Sufficient 
holding current to maintain the cell at –60 mV was applied through 
the amplifier headstage (Multiclamp 700A; Axon Instruments Inc.); this 
also assisted the seal formation. Once a seal with more than a giga Ohm 
resistance was formed, the pressure in the electrode was normalized 
to atmospheric pressure. The cell membrane under the electrode was 
ruptured by gentle suction, and cellular capacitance and resistance were 
manually compensated. Throughout the recording, both intracellular 
access and membrane capacitance were monitored, and only cells that 
showed stable access resistance were used for data analysis.
I-V relationships. The I-V relationships (current voltage curves) were exam-
ined using current clamp recording. A series of current injections (100 ms 
duration, from –50pA to 50 pA with an increment of 5 pA) were delivered 
to the recorded neuron. The I-V relationship was obtained from the above 
experiments, and membrane conductance of the recorded neuron was 
determined. The protocol was run several times and the response averaged. 
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